Organization
Poznan University of Medical Sciences and Greater Poland Cancer Center
1 abstract
Abstract
Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.Org: Istituto Nazionale Tumori IRCCS Fondazione Pascale, Hospital Universitario Virgen Macarena, Maria Skłodowska-Curie National Institute of Oncology Center, Poznan University of Medical Sciences and Greater Poland Cancer Center, UPMC Hillman Cancer Center,